Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397

Plain-language summary

This study investigates biomarkers (disease-related markers) in patients with metastatic or recurrent head and neck cancer treated with Cisplatin and Cetuximab on a prior clinical trial (ECOG-E5397). It included patients enrolled on that trial. It is an observational (non-phase) study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Eastern Cooperative Oncology Group

Intervention

cetuximab, cisplatin, gene expression analysis, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis

Start date

11/11/2011

Estimated completion

1/11/2012

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

DISEASE CHARACTERISTICS:

* Treated on protocol ECOG-E5397

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics